Silence Therapeutics (NASDAQ:SLN) Now Covered by The Goldman Sachs Group

The Goldman Sachs Group started coverage on shares of Silence Therapeutics (NASDAQ:SLN) in a research note published on Tuesday, MarketBeat Ratings reports. The firm issued a sell rating and a $6.00 price objective on the stock.

Other analysts also recently issued reports about the company. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Chardan Capital restated a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a research report on Tuesday, December 10th. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Finally, HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a report on Wednesday, January 29th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.00.

Silence Therapeutics Stock Performance

Shares of NASDAQ SLN opened at $4.16 on Tuesday. The firm has a 50 day moving average price of $6.26 and a two-hundred day moving average price of $12.96. The stock has a market cap of $124.51 million, a P/E ratio of -2.65 and a beta of 1.05. Silence Therapeutics has a 52-week low of $4.06 and a 52-week high of $27.72.

Hedge Funds Weigh In On Silence Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Values First Advisors Inc. bought a new stake in shares of Silence Therapeutics in the 3rd quarter valued at $56,000. GAMMA Investing LLC increased its stake in Silence Therapeutics by 609.2% in the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after purchasing an additional 5,233 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Silence Therapeutics during the fourth quarter valued at about $69,000. Verition Fund Management LLC bought a new position in shares of Silence Therapeutics during the 3rd quarter worth about $207,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Silence Therapeutics in the 3rd quarter valued at about $318,000. 98.73% of the stock is currently owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.